No approval for Sputnik V vaccine yet; Drug authority seeks additional data from Dr Reddy’s

An expert panel of India’s central drug authority has sought additional data and information from Dr Reddy’s Laboratories, which has sought emergency use authorisation for Russian Covid-19 vaccine Sputnik V, while deferring its decision on it till the next meeting, sources said.

In light of a February 24 meeting of the Subject Expert Committee (SEC) on Covid-19 of the Central Drugs Standard Control Organisation (CDSCO), the firm presented the interim safety and immunogenicity data of the Gam-Covid-Vac combined vector vaccine generated in the country, along with the interim data from the ongoing Russian study.

According to the sources, the SEC, which deliberated on the EUA application on Thursday, recommended that the firm should present data pertaining to all immunogenicity parameters, unblinded data of serious adverse events and RT-PCR positive cases, along with causality analysis reported till date for further examination.

“It has also asked the Hyderabad-based firm to submit a comparative analysis of the phase 3 immunogenicity data generated on the Indian and Russian studies at various time points. It has also asked the drug-maker to submit the factsheet,” a source said.

“We have had our meeting with the SEC today and will await the feedback from the CDSCO. We will provide an update once we have the feedback,” Dr Reddy’s Laboratories said in a statement.

On February 19, the firm said it had approached drugs regulator DCGI for emergency use authorisation (EUA) for Sputnik V.

In September last year, Dr Reddy’s partnered with the Russian Direct Investment Fund (RDIF) to conduct the clinical trials of Sputnik V and for its distribution rights in India.

The Drugs Controller General of India (DCGI) has already given the EUA nod to two COVID-19 vaccines — Covaxin of Bharat Biotech and Covishield of Oxford-AstraZeneca, being manufactured by the Serum Institute of India in Pune.

Sputnik V has demonstrated an efficacy rate of 91.6 per cent in the interim analysis of phase 3 clinical trial, which included data on 19,866 volunteers in Russia.

  • Related Posts

    Drug Department Raids Patna’s Govind Mitra Road Medicine Market Over Suspected Illegal Sale Of Medicines

    Three teams inspected several wholesale medicine shops following complaints of sales without bills, storage irregularities and alleged illegal trading of government-supplied medicines. Patna: The Drug Department has launched an inspection…

    ‘Forthwith’ Under Drugs Act Does Not Mean Immediate Dispatch of Seized Drug Samples: Karnataka HC

    Bengaluru: The Karnataka High Court has refused to quash a prosecution against a pharmaceutical firm and its managing partner under Sections 18(a)(i) and 27(d) of the Drugs and Cosmetics Act,…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Drug Department Raids Patna’s Govind Mitra Road Medicine Market Over Suspected Illegal Sale Of Medicines

    Drug Department Raids Patna’s Govind Mitra Road Medicine Market Over Suspected Illegal Sale Of Medicines

    ‘Forthwith’ Under Drugs Act Does Not Mean Immediate Dispatch of Seized Drug Samples: Karnataka HC

    ‘Forthwith’ Under Drugs Act Does Not Mean Immediate Dispatch of Seized Drug Samples: Karnataka HC

    A Worthy New Leader takes the Torch @Sir Ganga Ram Hospital

    A Worthy New Leader takes the Torch @Sir Ganga Ram Hospital

    CBI arrests two NCB staffers for demanding Rs 25 lakh bribe from a chemist in UP

    CBI arrests two NCB staffers for demanding Rs 25 lakh bribe from a chemist in UP

    Delhi Police bust fake Unani healthcare call centre in Pitampura; 12 arrested

    Delhi Police bust fake Unani healthcare call centre in Pitampura; 12 arrested

    Sakeena Itoo reviews functioning of Drug Testing Laboratory, GMC Kathua

    Sakeena Itoo reviews functioning of Drug Testing Laboratory, GMC Kathua